Resources
127 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 10/7/2019 (updated 3/25/2024)
Mapping Your Way from Vision to Impact: Strategic Planning Tools and Tips (Panel Discussion) Presentation and Resources.
Posted 10/7/2019 (updated 3/25/2024)
The Adopting a Shared Framework for Community Collaboration webinar addresses new questions and comments about the development of a shared public health framework, strategic planning, consortium partners, and opioid use disorder treatment.
Posted 10/7/2019 (updated 3/25/2024)
Mapping Your Way from Vision to Impact: Strategic Planning Tools and Tips Webinar Presentation and Materials
Posted 10/7/2019 (updated 3/25/2024)
An Introduction to Harm Reduction Webinar Presentation and Materials
Posted 10/7/2019 (updated 3/25/2024)
Adopting a Shared Framework for Community Collaboration Webinar and Resources
Posted 11/19/2019 (updated 3/25/2024)
Although typically delivered via intramuscular or intravenous injection, naloxone may be delivered via intranasal spray device.
Posted 1/25/2022 (updated 3/26/2024)
RCORP-TA is pleased to provide technical assistance resources related to grantee business operations that we have prepared for grantees. RCORP-TA is providing these resources to assist grantees on aspects of their business operations that are continuously impacted and routinely challenged by factors associated with living and working in rural communities. Please see the below linked guidance documents and descriptions as they may be of interest to you.
Posted 7/28/2023 (updated 3/26/2024)
Researchers interviewed 20 individuals – clinicians, peer support specialists, cultural practitioners, and others familiar with OUD treatment – in a Minnesota tribal community. The Cascade of Care model measures the quality of outcomes at each stage of treatment, from diagnosis to long-term maintenance, and was first proposed in 1998 as an approach to care for HIV/AIDS.
Posted 7/31/2023 (updated 3/26/2024)
At the end of July 2023, the U.S. Food and Drug Administration approved a second over-the-counter naloxone nasal spray product, RiVive. The agency who received the approval to manufacture the product, Harm Reduction Therapeutics, does not yet have a timeline of availability and decision on pricing.
Posted 7/31/2023 (updated 3/26/2024)
This presentation will cover health equity regarding rural American Indian and Alaska Native (AI/AN) communities' prevention and treatment efforts to address substance use disorder (SUD), including the need for contingency management for stimulants.